Experiences with

Obinutuzumab

https://cllsociety.org/2024/12/acalabrutinib-and-obinutuzumab-for-frontline-cll-treatment/

Anyone have treatment similar to this opposed to starting venetoclax on cycle 2 of obinutuzumab?

This will start with obinutuzumab with venetoclax to be added in 3 weeks. Are these the standard drugs used? I’ve been due to start treatment previously (2 years ago) and the drugs were different then. Appreciate things move quickly. Thanks all Alan

I received six months of obinutuzumab And 400 mg Venetoclax. My oncologist did a bone marrow biopsy and a CT scan. The results of the CT scan were all normal lymph nodes and the results of the bone marrow biopsy were clear of any disease.

Originally it was Venetoclax plus obinutuzumab. What is the difference, we have an appointment on the 18th to discuss but I just want to be clear. Mum has been doing well but suddenly her spleen has slightly enlarged and her hemoglobin has dropped. She is slightly anemic.

But you don't realise how slowly Cll changes things well I didn't anyway, so you go along thinking things are normal but there not once I had the 100mg sample of Obinutuzumab I felt different and after the rest on the 2nd day I was energised felt good but that might just be me.

I’m on the Pirtobrutinib , Venetoclax, Obinutuzumab trial for Richters. The rash looks like a salmon color bruise. It doesn’t hurt, itch, or change in size. There is no other rash on my body. It’s a curiosity that I wonder if anyone else has experienced?

A Young Mom Confronts “Skyrocketing White Blood Cell Counts” https://www.patientpower.info/video/chronic-lymphocytic-leukemia/a-young-mom-confronts-skyrocketing-white-blood-cell-counts Kylie's blog about her venetoclax + trial https://www.courageloveandlegacy.com/

Hi All had my two first infusions on Tuesday and Wednesday no issues at all despite some posts I have seen. Steroids did cause sleeping issues later but I did enjoy the pre meds. Blood results showed from Tuesday infusion showed slightly raised 222k to 232k. With get Bloods redone next Tuesday before

i started OV treatment in April and have finished the cycles of Obinutuzumab. My Venetoclax dose has been changed a number of times due to counts.

🙄 He has given me notes on my treatment - Obinutuzumab and Venetoclax. Two days in hospital and and at least 3 in outpatients, to start off with. Oh and he's said go on your holiday now, and come back in 6 weeks. That's all. Love and blessings to everyone!

With the obinutuzumab regimen, however, OS was significantly improved only after censoring for COVID-19 deaths, said Brown.

Matthew Davids, MD, MMSC, presented findings that a time-limited regimen of acalabrutinib, venetoclax, and obinutuzumab (AVO), guided by measurable residual disease (MRD), showed positive results.

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): A multicentre, single-arm, phase 2 trial. [i]The Lancet. Oncology[/i], S1470-2045(24)00396-6.

Hi All Started this on the 9th. 100ml then remainder on the 10th July. No reactions at all bloods taken on the 9th after trial infusion showed slight increase from 222k to 232k. remainder on the 10th all ok had a blood test yesterday. WBC was 232k now on the 15th July 3900 Its amazing, unbelievable

Obinutuzumab and Venetoclax 12 x 28 days Cycles. I will be at the Churchill in Oxford even though I live in Northants.

I’m in the Pirtobrutinib, Venetoclax, Obinutuzumab trial that started May of this year. I got a PET/CT scan in late April before the trial began. When I met with my Doc after the end of Cycle 4 for the first results of the PET/CT to determine if trial was working, he was ecstatic.

Clinical trials MRD Resistance mutations Figure 1: When to use a covalent BTK inhibitor vs venetoclax plus obinutuzumab in CLL or SLL. Figure 2: Treatment algorithms for CLL or SLL.

abstract in advance of the European Hematological Association Congress June 13-16, 2024: https://library.ehaweb.org/eha/2024/eha2024-congress/422268/nitin.jain.combined.pirtobrutinib.venetoclax.and.obinutuzumab.in.first-line.html [i]Abstract: S164 Title: COMBINED PIRTOBRUTINIB, VENETOCLAX, AND

for patients with chronic lymphocytic leukemia https://www.healio.com/news/hematology-oncology/20240828/measurable-residual-disease-status-predicts-pfs-for-patients-with-chronic-lymphocytic-leukemia [i]Rios-Olais and colleagues used data from prospective trials that evaluated targeted agents or obinutuzumab